Enanta Pharmaceuticals (ENTA) Total Liabilities (2012 - 2026)

Enanta Pharmaceuticals has reported Total Liabilities for 15 years, with the latest figure at $198.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 13.66% year-over-year to $198.1 million; the trailing twelve-month figure through Mar 2026 stood at $198.1 million (down 13.66% YoY), and the FY2025 full-year result was $216.0 million, down 12.84% from the prior year.
• Total Liabilities for Q1 2026 stood at $198.1 million, down from $202.9 million in the prior quarter.
• The five-year high for Total Liabilities was $257.3 million in Q2 2023, with the low at $46.7 million in Q4 2022.
• Historically, Total Liabilities has averaged $179.0 million across 5 years, with a median of $221.8 million in 2025.
• Annual changes were most pronounced in 2022 — Total Liabilities decreased 16.92% — and 2023, when it soared 445.34%.
• Enanta Pharmaceuticals' Total Liabilities stood at $46.7 million in 2022, then surged by 406.7% to $236.6 million in 2023, then increased by 0.09% to $236.8 million in 2024, then slipped by 14.32% to $202.9 million in 2025, then dropped by 2.36% to $198.1 million in 2026.
• The last three Total Liabilities figures came in at $198.1 million (Q1 2026), $202.9 million (Q4 2025), and $216.0 million (Q3 2025), per Business Quant data.